title: Role of "old" pharmacological agents in the treatment of Cushing's syndrome.
abstract: Despite recent advances in the management of endogenous Cushing's syndrome (CS), its treatment remains a challenge. When surgery has been unsuccessful or unfeasible as well in case of recurrence, the "old" pharmacological agents represent an important alternative for both ACTH-dependent and independent hypercortisolism. Especially in the latter, the advent of novel molecules directly targeting ACTH secretion has not outweighed the "old" drugs, which continue to be largely employed and have recently undergone a reappraisal. This review provides a survey of the "old" pharmacological agents in the treatment of CS.
authors.affiliation: Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.|Neuroendocrinology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy.
authors.forename: A G
authors.initials: AG
authors.lastname: Ambrogio
authors.affiliation: Neuroendocrinology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy. cavagnini@auxologico.it.
authors.forename: F
authors.initials: F
authors.lastname: Cavagnini
mesh_terms: D018674:Adrenergic Antagonists / Q000494:pharmacology*; D000818:Animals; D003480:Cushing Syndrome / Q000188:drug therapy*; D006801:Humans
chemical_list: D018674:Adrenergic Antagonists
keywords: Adrenal blocking agents; Cabergoline; Cushing’s disease; Cushing’s syndrome; Efficacy; Medical therapy; Mifepristone; Pasireotide; Side effects